Lipid-based drug delivery systems in the form of triglyceride emulsions, micellar systems and liposomes have been used for parenteral administration for the last few decades. Large number of new chemical entities (NCE) presents formulation and bioavailability problems because of the dose and poor solubility in solvent and co-solvent systems. In addition, high drug concentrations can lead to irr...

PURPOSE The purpose of the study was to develop and evaluate different lipid-based formulations for parenteral administration, as potential novel carrier systems for lipophilic drugs, and to turn an unstable drug such as chlorambucil into a useful one. METHODS A two-stage, high-pressure homogenizer was used to yield a very fine monodispersed lipid nanosphere. The strategy of combining egg yol...

Solid lipid nanoparticles (SLN) have been reported to be an alternative system to emulsions, liposomes, microparticles and their polymeric counterparts for various application routes since the early 1990s due to their advantages. Solid lipid nanoparticles colloidal drug carrier system gained a lot of popularity among researcher as colloidal drug carriers for incorporating hydrophilic or lipophi...

Lipid-based innovations have achieved new heights during the last few years as an essential component of drug development. The current challenge of drug delivery is liberation of drug agents at the right time in a safe and reproducible manner to a specific target site. A number of novel drug delivery systems has emerged encompassing various routes of administration, to achieve controlled and ta...

INTRODUCTION Nanoparticles are rapidly developing as drug carriers because of their size-dependent properties. Lipid nanoparticles (LNPs) are widely employed in drug delivery because of the biocompatibility of the lipid matrix. AREAS COVERED Many different types of LNPs have been engineered in the last 20 years, the most important being solid lipid nanoparticles (SLNs), nanostrucured lipid ca...

INTRODUCTION Gemcitabine hydrochloride is an antimetabolite (pyrimidine analog) with poor oral bioavailability (9%) due to the first pass metabolism. GEM is a water soluble drug (log p = -1.4) with a short half-life of 42 to 94 minutes (short infusions) and 245 to 638 minutes (long infusions) respectively. Extensive first pass metabolism, low bioavailability, high dosing frequency and less half...

Sterodin is a novel non-specific immunostimulating drug produced by a combination of bile lipids and bacterial metabolites. In the present study, we investigated some of its (i) toxicological and (ii) pharmacological properties in vivo, and (iii) drug-lipid interaction (lipid peroxidation) in vitro. We also evaluated the possible (iv) Sterodin-induced lipid peroxidation as well as the effect of...